Last edition
News about "biotechnology company"
Sobi has acquired Arthrosi Therapeutics, adding phase III gout candidate pozdeutinurad (AR882) to its portfolio, with trial results expected in 2026.
Biotechnology Company | 11/02/2026 | By News Bureau
FDA Approves Tenpoint Therapeutics' Yuvezzi, First Dual-Action Eye Drop for Presbyopia
The US FDA has approved Yuvezzi (carbachol and brimonidine tartrate), the first dual-agent eye drop for presbyopia, offering significant near-vision improvement with favourable tolerability.
Biotechnology Company | 31/01/2026 | By News Bureau | 142
QureBio Reports Promising Phase Ib/II Data for Q-1802 in Advanced Gastric and GEJ Cancer
ASCO 2026 data show strong response rates and manageable safety for the bispecific antibody Q-1802 plus XELOX, supporting progression to a Phase III trial.
Biotechnology Company | 29/01/2026 | By News Bureau
Olatec Therapeutics presented MJFF-funded preclinical data showing its oral NLRP3 inhibitor dapansutrile delivered disease-modifying effects across two translational Parkinson’s disease mouse models.
Biotechnology Company | 21/01/2026 | By News Bureau | 147
Insilico Medicine and Hygtia Therapeutics have entered a co-development deal for ISM8969, an AI-designed, brain-penetrant NLRP3 inhibitor, with milestone payments of up to USD 66 million.
Biotechnology Company | 21/01/2026 | By News Bureau | 157
Brenig Therapeutics Initiates First-in-Human Study of BT-409, Advances BT-267 Parkinson's Programme
Brenig Therapeutics has launched a first-in-human Phase I study of BT-409, a brain-selective NLRP3 inhibitor, while advancing BT-267 toward Phase 1b and Phase II studies in Parkinson’s disease.
Biotechnology Company | 20/01/2026 | By News Bureau | 145
D3 Bio has received FDA IND clearance to initiate a Phase I trial of its KRAS G12D inhibitor D3S-003 and a Phase II combination study targeting KRAS G12C-mutant lung cancer.
Biotechnology Company | 19/01/2026 | By News Bureau | 210
Clover Biopharmaceuticals Completes Initial Enrollment in Phase II Trial of RSV Combination Vaccines
The Australia-based Phase II study is evaluating Clover’s protein-based combination vaccine candidates SCB-1022 and SCB-1033 targeting RSV, hMPV and PIV3 in older adults, using its proprietary Trimer-Tag technology.
Biotechnology Company | 12/01/2026 | By News Bureau | 120
Kadimastem Shareholders Approve Merger with NLS Pharmaceutics
The merger brings NLS and Kadimastem one step closer to creating a combined Nasdaq-traded biotechnology company with a robust portfolio of advanced therapies for neurodegenerative diseases and diabetes.
Biotechnology Company | 01/02/2025 | By Abha | 242
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy